Nonresectable hepatocellular carcinoma: Long-term toxicity in patients treated with transarterial chemoembolization - Single-center experience

被引:50
|
作者
Buijs, Manon [1 ]
Vossen, Josephina A. [1 ]
Frangakis, Constantine [1 ]
Hong, Kelvin [1 ]
Georgiades, Christos S. [1 ]
Chen, Yong [1 ]
Liapi, Eleni [1 ]
Geschwind, Jean-Francois H. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Div Vasc & Intervent Radiol, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA
关键词
D O I
10.1148/radiol.2483071902
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the toxicity profile of transarterial chemoembolization (TACE) at 6 months and 1 year after treatment in patients with hepatocellular carcinoma (HCC) in a standardized oncology protocol so that TACE could be compared with systemic chemotherapeutic regimens for liver cancer. Materials and Methods: The study was authorized by the institutional review board. Between January 2002 and January 2007, 190 patients (155 men, 35 women; median age, 65 years; age range, 18-84 years) with HCC who underwent TACE treatment were identified from a prospectively collected database. Clinical records of complete blood cell counts and chemical profiles at baseline and at 6 and 12 months after treatment were studied retrospectively. Toxicity was graded according to the common terminology criteria for adverse events (CTCAE). A transition ( survival) analysis perspective was used to estimate the distribution of toxicity grades. Patient survival from the first TACE session was calculated with Kaplan-Meier analysis. Results: Grade 3 or 4 toxicity 6 and 12 months, respectively, after treatment included leukocytopenia (7% and 19%); anemia (9% and 19%); thromobocytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and 18%); elevated aspartate aminotransferase (15% and 18%), alanine aminotransferase (10% and 18%), and alkaline phosphatase (8% and 18%) levels; hypoalbuminemia (10% and 19%); hyperbilirubinemia (10% and 22%); and alopecia (18%). The cumulative survival rate was 58% at 1 year, 39% at 2 years, and 29% at 3 years. These toxicity rates were considerably lower than those reported after treatment with currently used systemic chemotherapeutic agents. Conclusion: Study results show that TACE has a favorable long-term toxicity profile in patients with HCC. Data clearly support the role of TACE in the treatment of patients with nonresectable HCC. (c) RSNA, 2008.
引用
收藏
页码:346 / 354
页数:9
相关论文
共 50 条
  • [21] Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: A single-center experience in China
    Qiang Fang
    Qing-Song Xie
    Jiang-Ming Chen
    Shen-Liang Shan
    Kun Xie
    Xiao-Ping Geng
    Fu-Bao Liu
    Hepatobiliary & Pancreatic Diseases International, 2019, 18 (06) : 532 - 537
  • [22] Long-Term Outcome of Liver Transplantation versus Resection for Hepatocellular Carcinoma: A Single-Center Experience
    Lee, S.
    Hatfield, B.
    Khan, A.
    Asgharpour, A.
    Lee, H.
    Imai, D.
    Matherly, S.
    Sharma, A.
    Wedd, J.
    Saeed, I.
    Kumaran, V.
    Cotterell, A.
    Bruno, D.
    Levy, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S729 - S729
  • [23] Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma
    Kim, Young-Il
    Park, Joong-Won
    Kwak, Hee-Won
    Kim, Bo Hyun
    Lee, Ju Hee
    Lee, In Joon
    Kim, Tae Hyun
    Kim, Seong Hoon
    Koh, Young Hwan
    Kim, Hyun Beom
    Kim, Chang-Min
    LIVER INTERNATIONAL, 2014, 34 (08) : 1278 - 1286
  • [24] Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
    Scheiner, Bernhard
    Ulbrich, Gregor
    Mandorfer, Mattias
    Reiberger, Thomas
    Mueller, Christian
    Waneck, Fredrik
    Trauner, Michael
    Koelblinger, Claus
    Ferlitsch, Arnulf
    Sieghart, Wolfgang
    Peck, Markus
    Pinter, Matthias
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E847 - E847
  • [25] Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
    Scheiner, Bernhard
    Ulbrich, Gregor
    Mandorfer, Mattias
    Reiberger, Thomas
    Mueller, Christian
    Waneck, Fredrik
    Trauner, Michael
    Koelblinger, Claus
    Ferlitsch, Arnulf
    Sieghart, Wolfgang
    Peck-Radosavljevic, Markus
    Pinter, Matthias
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 850 - 858
  • [26] Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience
    Kedarisetty, Chandan K.
    Bal, Sipra
    Parida, Subhashree
    Jain, Mayank
    Bhadoria, Ajeet S.
    Varghese, Joy
    Venkataraman, Jayanthi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 11 (03) : 299 - 304
  • [27] Prognostic significance of comorbidities in elderly patients with Hepatocellular carcinoma (HCC) treated with Transarterial Chemoembolization: a Single Centre Experience
    Aravind, P.
    Thillai, K.
    Suddel, A.
    Karani, J.
    Lewis, D.
    Heaton, N.
    Kane, P.
    Alkadhimi, G.
    Sarker, D.
    Ross, P.
    ANNALS OF ONCOLOGY, 2016, 27 : 29 - 29
  • [28] Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report
    Takeru Ohtaka
    Shintaro Shiba
    Kei Shibuya
    Shohei Okazaki
    Yuhei Miyasaka
    Kento Tomizawa
    Masahiko Okamoto
    Tatsuya Ohno
    Clinical Journal of Gastroenterology, 2022, 15 : 771 - 775
  • [29] Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - A single-center analysis including 132 patients
    Allgaier, HP
    Deibert, P
    Olschewski, M
    Spamer, C
    Blum, U
    Gerok, W
    Blum, HE
    INTERNATIONAL JOURNAL OF CANCER, 1998, 79 (06) : 601 - 605
  • [30] Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report
    Ohtaka, Takeru
    Shiba, Shintaro
    Shibuya, Kei
    Okazaki, Shohei
    Miyasaka, Yuhei
    Tomizawa, Kento
    Okamoto, Masahiko
    Ohno, Tatsuya
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2022, 15 (04) : 771 - 775